NSE · Healthcare · Diagnostics & Research
EPS came in at 3.22 against a street estimate of 5.73 — a miss of 43.8%.
with an average price target of ₹681.00.
| Holder | Stake |
|---|---|
| HSBC Mutual Fund - HSBC Aggressive Hybrid Fund | 6.79% |
| Nippon Life India Trustee Ltd-a/c Nippon India Pharma Fund | 5.66% |
| ICICI Prudential Mutual Fund - ICICI Prudential Active Momentum Fund | 3.72% |
| Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Business Cycle Fund | 3.51% |
| Kotak Mahindra Life Insurance Company | 1.57% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 THYROCARE TECHNOLOGIES LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Consolidated Revenue: INR 240 Cr (+24% YoY); Standalone Revenue: I | 2026-07-23 |
| Quarterly results · Q1 FY27 THYROCARE TECHNOLOGIES LIMITED – Q1FY27 RESULTS SUMMARY HEADLINE NUMBERS • Consolidated Revenue: INR 240.02 Cr (24% YoY growth) • EBITDA: INR 77.27 | 2026-07-23 |
| Annual report FY2026 THYROCARE TECHNOLOGIES LIMITED — ANNUAL REPORT FY 2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue from operations: ₹774.27 cror | 2026-06-04 |
| Q4 FY26 earnings call THYROCARE TECHNOLOGIES LIMITED – Q4 FY '26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY '26 Standalone Revenue: INR 210 crores, up 21% year-on-year • Q | 2026-05-14 |
| Quarterly results · Q4 FY26 THYROCARE TECHNOLOGIES LIMITED – FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue (Standalone): Rs 774.27 crores (FY2025: Rs 63 | 2026-05-07 |
| Investor presentation THYROCARE TECHNOLOGIES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q4FY26 Consolidated Revenue: INR 224 Cr (+20% YoY) • Q4FY26 Reported EBITDA: IN | 2026-05-07 |
| Q3 FY26 earnings call THYROCARE TECHNOLOGIES LIMITED – Q3 FY'26 SUMMARY HEADLINE NUMBERS • Consolidated revenue: INR 196 crores, up 18% year-on-year • Stand-alone revenue | 2026-02-02 |
| Quarterly results · Q3 FY26 THYROCARE TECHNOLOGIES LIMITED – Q3 FY26 RESULTS SUMMARY HEADLINE NUMBERS • Revenue: ₹195.53 crore in Q3FY26, up 18% year-on-year • EBITDA: ₹57.64 c | 2026-01-28 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹7 / share ex-date Jun 23, 2026 | 2026-06-23 |
| Bonus issue | 2 : 1 ex-date Nov 28, 2025 | 2025-11-28 |
| Dividend | ₹7 / share ex-date Oct 24, 2025 | 2025-10-24 |
| Announcement | Date |
|---|---|
| Acquisition of preference shares in Trovera Healthcare as part of subsidiary sale consideration Thyrocare Technologies Limited's board approved the sale of its entire 100% stake in Nueclear Healthcare Limited (NHL), a wholly-owned subsidiary operating a radiology and diagnostic imaging | 2026-09-21 |
| Scheme of Amalgamation of Docon Technologies with API Holdings approved Thyrocare Technologies Limited announced that the National Company Law Tribunal (NCLT) has approved the merger of Docon Technologies Private Limited into API Holdings Limited on August 31, 2 | 2026-09-01 |
| Equity infusion in wholly owned subsidiary Think Health Diagnostics Thyrocare Technologies Limited has announced an equity investment in its wholly-owned subsidiary, Think Health Diagnostics Private Limited. This means the parent company is putting additiona | 2026-05-07 |
| Additional capital infusion in Tanzania subsidiary Thyrocare Technologies Limited, an Indian diagnostic company, announced that it is investing additional capital into its Tanzania-based subsidiary, Thyrocare Laboratories (Tanzania) Limited. | 2026-02-24 |
| Receipt of Awards intimation notified to exchange Thyrocare Technologies Limited has informed the Exchange regarding 'Intimation of receipt of Awards'. | 2026-01-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Thyrocare Technologies Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.